SCHEDULE: Vanguard Group Reduces Stake in FibroGen to 4.4%

The Vanguard Group has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.4% in FibroGen Inc.'s common stock.

Summary

• The Vanguard Group reported beneficial ownership of 178,040 shares of FibroGen Inc. common stock.
• This aggregate amount represents 4.40% of FibroGen Inc.'s outstanding common stock.
• The Vanguard Group holds sole dispositive power over 176,616 shares and shared dispositive power over 1,424 shares.
• The firm holds no sole or shared voting power over these shares.
• The filing is an Amendment No. 12 to a Schedule 13G, indicating previous filings for a larger stake.
• The filing states the event date requiring this statement was June 30, 2025, and the signature date was July 29, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of ownership and does not inherently convey positive or negative sentiment about the company's performance, though a reduction in stake by a major investor could be perceived negatively.

Positives

• NA

Negatives

• The reduction of The Vanguard Group's stake to below 5% suggests a decrease in their position, which could be interpreted negatively by the market.

Risks

• NA

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding FibroGen Inc.'s future outlook.

Management Comments

• The Vanguard Group certifies that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose or with the effect of changing or influencing the control of FibroGen Inc.

Industry Context

This filing is a routine disclosure of an institutional investor's passive ownership stake and does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The disclosure of a reduced stake by a significant institutional investor like The Vanguard Group may influence investor sentiment and potentially the stock price.

Key Dates

Keywords

FibroGen Inc., Vanguard Group, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Institutional Investor, Equity Stake